Inhibrx Cancer-Drug Combination Produces About 63% Response Rate In Ewing Sarcoma Trial
Median time without cancer progression was six months, versus historical chemotherapy benchmarks of three to four months cited by the company.
Inhibrx Biosciences, which develops experimental biologic cancer therapies, reported Tuesday that an ozekibart-and-chemotherapy combination produced an about 63% response rate in evaluable Ewing sarcoma patients. The company’s SEC filing and attached release put that result against historical chemotherapy-alone response rates of approximately 15% to 30%.
Tumor Responses And Their Durability
The early-to-mid-stage trial combined ozekibart with irinotecan and temozolomide in patients whose Ewing sarcoma had returned or resisted treatment. Among 51 patients evaluable for response, two had complete responses and 30 had partial responses.
Patients went a median six months without cancer progression. Inhibrx cited historical results of roughly three to four months for irinotecan and temozolomide alone; those benchmarks are historical comparisons, not results from a chemotherapy-only group in this study.
Measurable tumor shrinkage occurred in 43 evaluable patients, or 84.3%. Another 12 patients had stable disease, bringing the disease-control rate—responses plus stable cancer—to 86.3%.
Benefit persisted beyond six months for 18 patients: one with a complete response, 16 with partial responses and one with stable disease. A partial response in one patient was still ongoing beyond two years.
Patients Still Receiving Treatment
The study had treated 60 patients, including nine adolescents, by the September 18, 2026, cutoff. Twenty-two were still receiving treatment.
Fourteen evaluable patients had not experienced progression at the cutoff, including two whose time without progression exceeded 12 months. The reported median came with a 95% confidence interval of 4.6 to 7.4 months.
Inhibrx characterized the side effects as manageable and consistent with the known toxicities of the chemotherapy drugs and DR5 activation. It said there was no evidence of unexpected liver toxicity accumulating with treatment.
The company estimated that approximately 300 new Ewing sarcoma cases are diagnosed annually in the U.S., where an estimated 2,500 people live with the disease.
“Based on these results, we intend to rapidly advance our plans with the goal of allowing patients access as soon as possible,” said Mark Lappe, chief executive officer of Inhibrx Biosciences.
Chondrosarcoma Launch Preparations Are Already Underway
Ozekibart targets DR5, a receptor involved in cell death. Inhibrx uses its own protein-engineering platforms to develop biologic therapies and has no approved products. Its clinical pipeline includes ozekibart and ordastobart, also called INBRX-106.
The FDA has accepted for filing Inhibrx’s application seeking ozekibart approval for conventional chondrosarcoma, a separate cancer indication. Acceptance starts the application review; it is not approval.
Administrative expenses rose to $7.8 million from $5.3 million a year earlier in third-quarter results released Friday. Inhibrx attributed the increase to market-access efforts, launch preparations and communications materials.
Research and development spending fell to $26 million from $28.5 million. The company attributed part of that decline to finishing enrollment in its chondrosarcoma trial.
Varun Monga, M.D., is scheduled to present the Ewing sarcoma results on Thursday at the Connective Tissue Oncology Society annual meeting.
Sources
- 8-K Filing — Inhibrx Biosciences, Inc. (INBX) — SEC EDGAR
- Exhibit exhibit991-pressreleasenov.htm — Inhibrx Biosciences, Inc. 8-K exhibit — SEC EDGAR
- Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma — prnewswire.com
- Inhibrx Reports Third Quarter 2026 Financial Results — prnewswire.com